Grandazol solution for infusions 5 mg/2.5 mg/ml. 200 ml. № 1 vial

Description

GRANDAZOL COMPOSITION

active ingredients: ornidazole; levofloxacin; 1 ml of ornidazole 5 mg, levofloxacin 2.5 mg excipients: sodium edetate, sodium chloride, water for injection.

GRANDAZOL DOSAGE FORM

Solution for infusion. Basic physical and chemical properties: transparent colorless or light yellow liquid.

GRANDAZOL PHARMACO-THERAPEUTIC GROUP

Antimicrobial agents for systemic use. Levofloxacin, combinations with other antibacterial agents. ATX code J01R A05.

PHARMACOLOGICAL PROPERTIES

Levofloxacin Pharmacodynamics Levofloxacin is a synthetic antibacterial drug of the fluoroquinolone group and the S-enantiomer of the racemic mixture of the drug ofloxacin. Mechanism of action As an antibacterial drug of the fluoroquinolone group, levofloxacin acts on the DNA-DNA gyrase complex and topoisomerase IV. Pharmacokinetics / pharmacodynamics ratio The degree of bacterial activity of levofloxacin depends on the ratio of the maximum serum concentration (max) or the area under the pharmacokinetic curve (AUC) and the MIC (inhibitory) concentration (MIC (MIC)). Mechanism of resistance The main mechanism of resistance is a consequence of a mutation in the gyr-A genes. In vitro cross-resistance exists between levofloxacin and other fluoroquinolones. Due to the mechanism of action, there is usually no cross-resistance between levofloxacin and other classes of antibacterial agents. Antibacterial spectrum The prevalence of resistance in selected species may vary geographically and in order to obtain local information on resistance, especially in the treatment of severe infections. If necessary, you should seek the advice of a specialist when the local prevalence of resistance is such that the usefulness of the drug, at least for some types of infections, is questionable.

INDICATIONS

Treatment of mixed urinary tract infections caused by pathogens (microorganisms and protozoa) sensitive to the components of the drug. Treatment of acute respiratory tract infections. Prevention of pyoinflammatory complications after surgical interventions on the abdominal organs. Prevention of pyoinflammatory complications after gynecological operations.

CONTRAINDICATIONS OF GRANDAZOLE

Hypersensitivity to levofloxacin or other fluoroquinolones, ornidazole or other nitroimidazole derivatives and other components of the drug; glucose-6-phosphate dehydrogenase deficiency; organic diseases of the central nervous system, epilepsy, multiple sclerosis; complaints of side reactions from the tendons after prior use of quinolones; circulatory disorders, abnormal blood lesions or other hematological abnormalities; chronic alcoholism; children’s age (up to 18 years old); pregnancy; lactation period.